Welcome to issue #62 of FutureFemHealth, here to bring you your weekly news about womenâs health innovation and FemTech (w/c 22 July 2024).
đ Coming up today weâve got:
đ¤°đźÂ $26m Series A for Novocuff to tackle preterm births
â¤ď¸Â HPV self-sampling tests one-step closer after NHS trial
đ First-time IVF patients now aged 35+ for first time, says new HFEA data
đđźÂ âDream come trueâ drug could extend female fertility by five years
Got news to share from the world of FemTech and womenâs health innovation? Want to sponsor our newsletter? Let me know at anna@futurefemhealth.com
đ¤°đźTaking on the challenge of preterm births
Improving maternal and neonatal care can sometimes seem like a near-insurmountable challenge.
Headlines and data constantly highlight deep-seated issues: maternal deaths, racial disparities, preterm births, and postpartum mental health.
But then, a start-up comes along with a targeted solution that offers real hope for meaningful progress.
Actually, make that two start-ups.
Novocuff and PregnanTech are both working to reduce the devastation of preterm births.
Preterm birth is the leading cause of death for infants under the age of one. An estimated one million babies die each year due to preterm birth complications - with many others facing long-term health issues.
Every extra day a baby can stay in the womb is crucial.
And the financial and emotional burden is also overwhelming. In the US, the cost of treating a preterm newborn is ten times that of a full-term baby. And women who have had preterm delivery experience significantly higher levels of stress and depression.
Last week, Novocuff closed an oversubscribed $26 million Series A funding round.
Founders Amelia âAmyâ Degenkolb and Donald Lee are developing a medical device that can stabilise and close the cervix if it begins to open prematurely during pregnancy.
Investor Curt LaBelle from AXA IM Alts commented:
âOur investment should enable completion of a US pivotal trial and the introduction of the Novocuff device to global markets, including low- and middle-income countries.â
Over in Israel, PregnanTech has developed LIONESS, a non-surgical silicone ring device similar to a pessary.
It can be inserted around the cervix as early as the 12th week of pregnancy in a quick non-surgical procedure that takes just a few minutes.
The ring keeps the cervix long and helps to prevent dilation, thereby extending pregnancy.
LIONESS has already shown promising outcomes in trials published in the American Journal of Obstetrics and Gynecology.
Next year, PregnanTech also plans a pivotal study in the US and will apply for FDA approval.
Both of these focused, problem-specific approaches from Novocuff and PregnanTech offer real hope on a global scale.
And by accumulating more solutions like these we can create the substantial positive change we all want - and need - to see in maternal and infant health outcomes.
đ°Â Funding, deals and investment news

đ US: Novocuff raises $26m to advance tech to reduce preterm births. See main story above for details. Funding round led by AXA IM Alts. (Continue reading: FutureFemHealth)
đ US: 3Daughters closes $4.7m seed funding round for novel IUD contraception. 3Daughtersâ small, magnetic and frameless IUD âself-assemblesâ in the uterus with no strings. A patented inserter and retriever helps to eliminate pain too. This round included participation from existing investors Thairm Bio. 3Daughters has now launched its Series A financing round of $15m to fund clinical trials next year. (Continue reading: FutureFemHealth)
đ MALAYSIA: Motherhood Care+ completes seed funding round. In Malaysia, confinement after birth is a common practice to regulate both physical and mental health. Start-up Motherhood Care+ integrates products and services from confinement centres, nannies and wellness providers into one platform and app, supporting women through pregnancy and the crucial 100 days post-birth. Funding was led by Care Ventures Group. Amount undisclosed. (Continue reading: FutureFemHealth)
đ US: TMRW Life Sciences raises $28m Series D to upgrade storage for egg freezing. TMRW takes on the risk of storing eggs, embryos and sperm for more than 63 fertility clinics in the UK and US (including for Kindbody). Its world-first and only FDA-cleared automated platform is said to reduce potential points of failure by 93% and make processes much more efficient for clinics. Funding was led by existing investor 5AM Ventures and will be used for further international expansion. (Continue reading: Endpointsnews)
đ More news from this week
đ US: Womenâs health and hormonal health driving interest and growth in vitamins, minerals and supplements (VMS) sector. A new report from NYC-based VC firm XRC Ventures deep dives into the $60billion VMS sector. It finds that increased general interest in health and wellbeing as well as growing awareness of hormonal health and the destigmatisation of womenâs health continues to result in a growing number of start-ups to meet consumer demand. Seven other key trends in the VMS sector are identified including longevity and GLP-1s. (Continue reading: FutureFemHealth)
đ GLOBAL: The no-brainer menopause treatment that nobody is talking about. Itâs safe, localised and relieves a slew of painful symptoms related to the genitourinary syndrome of menopause (GSM) - which affects as many of 84% of women during and following menopause. So why is vaginal (o)estrogen, which is both preventative and restorative, not more widely available? This is a brilliant overview of an important (and cheap) treatment. (Continue reading: Oprah Daily)
đ US: More teen-focused period-care startups are entering wholesale. Period care brand Pinkie will launch in CVS this month. Itâs an example of how small, disruptor brands are getting more recognition from wholesalers, thanks to growing consumer demand for more diverse and innovative products. (Continue reading: Modern Retail)
đ US: Saaltâs menstrual cup sees sales triple after tampon study. Yes, that tampon study has caused plenty of concern about the safety of tampons - albeit with many unanswered questions that need more research. But the impact is apparently being felt: Saalt, which sells menstrual cups and period underwear, says it has seen a 95% increase in its website sales and a 109% increase in online orders. (Continue reading: Boise Dev news)
𩸠Research and womenâs health news
đ UK: âGame-changingâ HPV self-sampling tests one-step closer after NHS trial. Currently the UKâs cervical screening programme requires people to go into their GP surgery - yet 1 in 3 of those invited do not go. A self-sampling vaginal swab, designed for people who havenât attended cervical screening, has seen success in a trial in 133 London GP practices. It suggests that if self-sampling was rolled out on the NHS more widely it could enable a million more women to get tested for HPV in three years. Self-sampling is already introduced in countries such as The Netherlands, Australia, Denmark and Sweden. (Continue reading: Eve Appeal)
đ UK: Fertility patients are starting treatment when chances of having a baby fall, says HFEA. Itâs time for annual trends and figures from the Human Fertilisation and Embryology Authority (HFEA). For the first time, the average age of first-time patients is now over 35-years-old. HFEAâs chair Julia Chain has since hit back at media coverage which inferred that women are starting IVF too late. She said âwe do not judge, blame or criticise those who are accessing treatment at any stage.â (Continue reading: HFEA)
đ US: âDream come trueâ: study suggests drug could extend womenâs fertility by five years. A cheap and generic drug called Rapamycin could decrease ovarian ageing by 20%, providing hope for age-related fertility issues, while also delaying menopause, post-menopausal health issues and perhaps even extending lifespan. A world-first, albeit small trial, will now scale up to provide more evidence. Yet as co-lead researcher Yousin Suh commented: âthereâs no motivation for pharmaceutical companies to invest because thereâs no possibility of making money from an off-patent drug.â (Continue reading: The Guardian)
đ UK: Air pollution and pregnancy: how air pollution impacts us from the beginning. Air pollution impacts our everyday life, but there is also a lot of emerging literature on the impacts of air pollution on fertility, pregnancy and the health of babies and their mothers. In this article, Air Aware Labs delves into the evidence we have so far. (Continue reading: Air Aware Labs)
đ GLOBAL: Why sex bias in labs means women are the losers in research into ageing. In laboratories worldwide, cages are filled with mice for human research. And they all share one thing in common - they are all male. The impact of this is staggering: about 75% of the drugs that extend lifespan in mice work only on males. When researchers belatedly tested the drugs on both sexes they discovered females did not respond. This is an eye-opening piece well worth a read - there are many more shocking examples I canât squeeze in here! (Continue reading: The Guardian)
đ Govt & policy news
đ US: Womenâs health in a âperilous place.â Where a woman lives matters to her health with âclear distinctionsâ across US states when it comes to access to care, quality of care and health outcomes. The latest 2024 State scorecard from Commonwealth Fund says there are deep and growing inequalities that need urgent action. (Continue reading: The Guardian)
đ UK: Itâs time to prioritise womenâs reproductive health. 800 clinicians and 60 leading organisations have called upon the new Government to improve the health of the 51% and prioritise womenâs reproductive health. Led by The Faculty of Sexual and Reproductive Healthcare, an open letter highlights shocking health inequalities for urgent action, including maternal mortality in Black women and women of Asian and mixed ethnicity. (Continue reading: FSRH)
đ US: Where does Kamala Harris stand on womenâs health issues? After a momentous week in American politics that saw President Joe Biden pull out of the election race, Vice-President Kamala Harris is now the likely Democratic nominee for upcoming election. This article highlights her track record on womenâs health - championing reproductive rights and pushing to make Black maternal health a national priority. (Continue reading: Womenâs Health Magazine)
â
 Jobs
đ UK: Conversational Content Designer (fixed-term, 14 months), Flo Health
đ UK: Investment Manager, Exceptional Ventures
đ US: Head of Growth, Evvy
And finallyâŚ.

Help us lift the lid on discrimination facing FemTechâŚ
Weâre working with The Guardian on a major investigation into the barriers that FemTech, womenâs health and sexual wellness companies face, and we need your help! Have you been turned down for banking, insurance, payment providers or e-commerce? Perhaps youâve been forced to pay a premium for insurance?
Please take 2 minutes to complete our survey (can be anonymously) so that we can raise awareness of the extent of this issue. If you operate in the UK, please take part here.
See you next time,
Anna



